Welcome to our dedicated page for Kraig Biocraft Laboratories In news (Ticker: KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories In stock.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) regularly issues detailed news releases about its work in recombinant spider silk and bioengineered fibers. The company describes itself as a world leader in spider silk technology and uses its news flow to report on production milestones, facility expansions, scientific progress, and commercial engagements.
News items often highlight advances in the company’s BAM-1 and BAM-1 Alpha hybrid silkworm lines, including selective breeding achievements that increase cocoon shell weight, throughput, and production efficiency. Kraig Biocraft Laboratories also reports on the launch and completion of spider silk production cycles, the deployment of BAM-1 Alpha as its primary production hybrid, and the integration of diapause egg management into its rearing operations.
Another recurring theme in KBLB news is the build-out of production infrastructure in Southeast Asia. Releases cover topics such as taking possession of additional silkworm rearing centers, relocating facilities to protected highlands, and maintaining multiple, parallel production sites to support scalability and resilience. The company also reports on securing usage rights to government-owned mulberry gardens and taking control of mulberry fields dedicated to its operations, emphasizing feedstock security and vertical coordination.
Investors and observers can also find updates on commercial and research developments, including pilot programs with a globally recognized performance sports apparel brand and announcements about scientific leadership and breakthroughs in advanced fibers and bioengineered materials. Together, these news items provide an ongoing view into Kraig Biocraft Laboratories’ efforts to expand spider silk production capacity, refine its technology, and pursue high-value applications in performance textiles, technical apparel, and other markets.
Kraig Labs (OTCQB:KBLB) is pursuing vertical integration in spider silk production by securing access to government-owned mulberry gardens near its Southeast Asia facilities, locking a critical biological feedstock. The release links this move to improved logistics, cost stability, and scale readiness for commercial spider silk super fibers.
The article frames vertical integration as a broader industry trend exemplified by SpaceX, Apple, and Amazon, highlighting how supply-chain ownership can reshape competitiveness for advanced materials and AI infrastructure.
Kraig Biocraft Laboratories (OTCQB: KBLB) is highlighted as a potential materials provider for next‑generation wearable systems using its recombinant spider silk superfibers, while AI, sensor, and compute firms could supply complementary technologies. Palantir is cited for data‑integration AI with projected Q4 2025 revenue of about $1.34B (up ~62% YoY) and adjusted EPS near $0.23. NVIDIA is noted for on‑device AI and a $2B investment in CoreWeave; TE Connectivity for rugged connectors and sensors. The piece frames an ecosystem view where materials, AI, and engineering converge toward advanced wearables.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced on January 20, 2026 that it has completed construction of its most advanced spider silk gene constructs and has begun active execution of a large-scale silkworm gene-engineering program. The initiative aims to substantially increase fiber strength and elasticity, expand production scalability, and advance commercial-scale recombinant spider silk manufacturing.
The company describes the program as its most ambitious genetic engineering effort to date and says it builds on years of proprietary research.
Kraig Biocraft Laboratories (OTCQB: KBLB) has taken possession of its third silkworm rearing center, completing core infrastructure upgrades for a 2026 production scale-up.
With three operational rearing centers the company says it can run three simultaneous production cycles and aims to exceed one metric ton of finished spider silk per month, supported by newly acquired mulberry fields for feedstock. Operations are expected to begin later this quarter.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced it has taken possession of three mulberry fields and integrated that feedstock into active silkworm rearing to advance a planned production ramp-up. Mulberry leaf from these fields will support deployment of more than 1,000,000 BAM-1 Alpha production hybrid eggs now scheduled for release. The fields' proximity to company facilities is cited as providing logistical efficiencies, feedstock consistency, and supply security. Kraig Labs also noted access to additional mulberry fields through a collaboration with a Southeast Asia government office, which the company says can remove fixed capacity constraints and support rapid growth toward sustained commercial output.
Kraig Biocraft Laboratories (OTCQB: KBLB) completed a production cycle delivering more than one million BAM-1 Alpha hybrid eggs on Dec. 15, 2025. The eggs are staged for release over the next quarter to support recombinant spider silk production.
The company says BAM-1 Alpha provides greater uniformity, resiliency, throughput and consistency, enabling an accelerated 6-month production schedule and supporting expansion initiatives in Southeast Asia.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced on Dec 8, 2025 that it has been granted usage rights to a block of government-owned mulberry gardens near its Southeast Asia spider silk production facilities. The company will pay a nominal rent and will incorporate the gardens into its production pipeline to supply mulberry leaf feedstock for scaled-up recombinant spider silk manufacturing, including BAM-1 Alpha hybrid yarns.
This land access is intended to improve supply reliability, logistics, and the company's ability to support a recently announced pilot order from a leading performance sports apparel brand as Kraig Labs advances toward broader commercialization.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced a hiring initiative on November 25, 2025 to expand production staffing at its Southeast Asia operations as throughput and its production footprint increase. The company is recruiting and training new production staff to support a new production center currently in development, with specialized sericulture training led by Dr. Nirmal Kumar.
The expansion aims to increase capacity, resilience, and commercial production of the company's recombinant spider silk over the coming quarters, and Kraig Labs said it expects to continue adding staff and resources as facilities are developed.
Kraig Biocraft Laboratories (OTCQB: KBLB) is fulfilling an order of its next-generation recombinant spider silk yarns for a confidential pilot program with a globally recognized performance sports apparel brand.
The company is converting part of its spider silk inventory into yarns tailored to the customer's specifications; delivery is expected before the end of the first quarter of 2026. The pilot uses a small, purpose-built quantity intended to demonstrate commercial and performance potential while details remain confidential.
Kraig Biocraft Laboratories (OTCQB: KBLB) confirmed on Nov 3, 2025 that its spider silk production operations in Vietnam remained fully secure and uninterrupted after recent Southeast Asia typhoons.
The company cited its 2024 relocation to protected highlands, complete September relocation from its former Quang Nam facility, and a strategy of multiple parallel production sites as the reasons operations and mulberry feedstock suffered no damage or disruption.
FAQ
What is the current stock price of Kraig Biocraft Laboratories In (KBLB)?
What is the market cap of Kraig Biocraft Laboratories In (KBLB)?
